MRCP Or ERCP Joint Tumor Marker Joint CA19-9in Pancreatic Cancer Diagnostic Value Of Discussion

Objective：Explore the diagnostic value of MRCP or ERCP joint tumor markerCA19-9detection of pancreatic cancer, pancreatic cancer diagnosis to provide aneffective, accurate, Specific diagnostic methods.Methods：Randomly selected from the Second Affiliated Hospital of NanchangUniversity2008.1-2012.1by pathology or ERCP biopsy diagnosis of pancreaticcancer patients, and the line MRCP or ERCP examination and serological CA19-9detection (CA19-9>37U/ml positive)122patients, including10patients with tumordiameter <2cm (pancreatic cancer)[1] patients, another randomly selected hospitalthe surgical pathology diagnosed line MRCP2008.1-2012.1did not undergo tumormarker CA19-9detection of pancreatic cancer patients48cases.112patients withpancreatic cancer based on the diagnostic method is divided into the MRCP jointCA19-9group (70cases) and ERCP combined with CA19-9group (42cases), theother48cases MRCP examination did not undergo tumor marker CA19-9testgroup MRCP alone group. Using t test, test MRCP combined group (MRCP UnitedCA19-9group), the ERCP joint group (ie, the ERCP United CA19-9) and a separatethe MRCP group of diagnosis of pancreatic cancer the accuracy of comparativeanalysis for clinical diagnosis of pancreatic cancerprovide an effective means.Result： MRCP joint group and the combined group of ERCP accuracy of thediagnosis of pancreatic cancer were95.7%and97.6%, P>0.05, the difference wasnot statistically significant; separate MRCP diagnosis rate of91.67%, the rate ofdiagnosis of the MRCP joint group compared separate MRCP group, the differencewas statistically significant (P <0.05)Conclusion：MRCP and ERCP combined group accurate diagnosis of pancreaticcancer combined group was no significant difference in positive rate compared withMRCP examination alone, it can be detected MRCP joint CA19-9as a reliable andeffective means of diagnosis of pancreatic cancer.